CinCor Pharma is a clinical-stage biopharmaceutical company focused on developing our lead clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases. We are conducting a Phase 2 clinical trial of CIN-107 in patients whose blood pressure is not controlled despite treatment with three antihypertensive agents and have recently initiated a separate Phase 2 clinical trial in patients with elevated aldosterone levels whose blood pressure is not controlled despite treatment with one antihypertensive agent. In addition to hypertension, we are developing CIN-107 for the treatment of primary aldosteronism and exploring its utility in ameliorating complications of chronic kidney disease.